Bradykinin is not only a mediator of pain and inflammation but also a potent vasodilator and is likely to contribute to the cardioprotective effects of angiotensin-converting enzyme inhibitors. The B2 receptor (B2-R) mediating most of the inflammatory and cardiovascular effects of bradykinin represents a candidate gene likely involved in the complex genetic causes of common chronic disorders such as hypertension. The C181T polymorphism of the B2-R gene influences the potency of bradykinin and there is evidence of a possible role of this polymorphism in the development of hypertension and end-stage renal disease. We developed and validated a new, rapid, and reliable method for the detection of the C181T polymorphism based on the hybridization probes format on the LightCycler, which is superior to the conventional PCR-RFLP method commonly used to detect this polymorphism. It allows the solid evaluation of large patient populations with the best time.